The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS Center.

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its ...

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.